Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares of Company Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $74.81, for a total transaction of $523,670.00. Following the completion of the transaction, the insider owned 31,771 shares of the company’s stock, valued at approximately $2,376,788.51. The trade was a 18.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Tuesday, September 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.38, for a total value of $734,143.86.
• On Monday, August 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $111.84, for a total value of $782,880.00.

Oruka Therapeutics Trading Down 3.7%

NASDAQ ORKA opened at $73.87 on Friday. The stock has a 50-day moving average of $92.99 and a 200 day moving average of $80.08. Oruka Therapeutics, Inc. has a one year low of $25.11 and a one year high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. UBS Group increased their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. BTIG Research reaffirmed a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 target price on shares of Oruka Therapeutics in a report on Thursday, September 24th. Guggenheim reaffirmed a “buy” rating and issued a $200.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Oruka Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $128.91.

Institutional Trading of Oruka Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Algert Global LLC lifted its position in shares of Oruka Therapeutics by 3.5% in the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock valued at $512,000 after acquiring an additional 180 shares in the last quarter. GAMMA Investing LLC boosted its stake in Oruka Therapeutics by 201.6% in the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock worth $31,000 after purchasing an additional 250 shares during the period. Nykredit A S purchased a new position in Oruka Therapeutics during the second quarter valued at $29,000. AlphaCentric Advisors LLC grew its stake in Oruka Therapeutics by 5.8% during the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after acquiring an additional 626 shares in the last quarter. Finally, Orion Capital Management LLC purchased a new position in Oruka Therapeutics during the second quarter valued at $91,000. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.